While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications for depemokimab ...